1196546-33-4 Usage
Uses
Used in Pharmaceutical Industry:
(R)-1-(6-(6-(2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-[2,4'-bipyridin]-2'-yl)piperidin-4-ol is used as a pharmaceutical compound for its potential role in treating neurological and psychiatric disorders. Its antagonistic action on the serotonin 5-HT2A receptor makes it a subject of interest for researchers exploring its therapeutic effects and pharmacological properties.
Used in Research and Development:
In the field of research and development, (R)-1-(6-(6-(2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-[2,4'-bipyridin]-2'-yl)piperidin-4-ol serves as a valuable compound for studying the serotonin 5-HT2A receptor's involvement in physiological and pathological processes. This can lead to a better understanding of the receptor's role in various conditions and the development of targeted therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 1196546-33-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,6,5,4 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1196546-33:
(9*1)+(8*1)+(7*9)+(6*6)+(5*5)+(4*4)+(3*6)+(2*3)+(1*3)=184
184 % 10 = 4
So 1196546-33-4 is a valid CAS Registry Number.
1196546-33-4Relevant academic research and scientific papers
(R)-2-Phenylpyrrolidine substituted imidazopyridazines: A new class of potent and selective pan-TRK inhibitors
Choi, Ha-Soon,Rucker, Paul V.,Wang, Zhicheng,Fan, Yi,Albaugh, Pamela,Chopiuk, Greg,Gessier, Francois,Sun, Fangxian,Adrian, Francisco,Liu, Guoxun,Hood, Tami,Li, Nanxin,Jia, Yong,Che, Jianwei,McCormack, Susan,Li, Allen,Li, Jie,Steffy, Auzon,Culazzo, Annemarie,Tompkins, Celine,Phung, Van,Kreusch, Andreas,Lu, Min,Hu, Bin,Chaudhary, Apurva,Prashad, Mahavir,Tuntland, Tove,Liu, Bo,Harris, Jennifer,Seidel, H. Martin,Loren, Jon,Molteni, Valentina
, p. 562 - 567 (2015/05/27)
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several chromosomal rearrangements involving TRKA have be
COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
-
Page/Page column 161, (2009/12/23)
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, c-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-1R, ALK4, ALK5 and ALK or combinations thereof.
